A Randomized, Open-Label, 3-Dose, 3-Period, Crossover Phase 2 Study Investigating the Tolerability and Pharmacokinetics of MAP0010 in Children 4 Through 11 Years Old With a History of Mild-To-Moderate Stable Asthma.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2014
At a glance
- Drugs Budesonide (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors MAP Pharmaceuticals
- 02 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Dec 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 21 Oct 2009 New trial record